Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait

Background: Venous thromboembolism (VTE) includes the abnormal clotting of blood in a deep vein of the upper or lower limbs (deep vein thrombosis) that may travel to and block a blood vessel in the lung (pulmonary embolism).

Locations

1 United States site

Age

18 to 80 Years

Genotypes

HbSS, HbSC, HbAS

LEARN MORE
Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease

Background: Sickle cell disease (SCD) is an inherited blood disorder.

Locations

1 United States site

Age

18 to 99 Years

Genotypes

HbSS, HbAS

Phase

Early Phase 1

LEARN MORE
Cognitive Behavioral Therapy and Real-Time Pain Management Intervention for Sickle Cell Via Mobile Applications

The investigators are conducting a comparative effectiveness trial among adult patients with sickle cell disease (SCD) who report chronic pain (N = 350), randomized to receive either mobile phone-delivered computerized cognitive behavioral therapy (cCBT; n = 175) or digital education (m-Education; n = 175).

Locations

5 United States sites

Age

> 18 Years

Phase

N/A

LEARN MORE
Evaluation of the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat

Background: Sickle cell disease (SCD) is a disorder that causes episodes of acute pain and progressive organ damage.

Locations

1 United States site

Age

18 to 70 Years

Genotypes

HbSS

Phase

Phase 1/Phase 2

LEARN MORE
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of FT-4202 and test how well FT-4202 works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).

Locations

23 United States sites

Age

12 to 65 Years

Phase

Phase 2/Phase 3

LEARN MORE
Sickle Cell Disease and CardiovAscular Risk – Red Cell Exchange Trial (SCD-CARRE)

The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.

Locations

16 United States sites

Age

> 18 Years

Phase

Phase 3

LEARN MORE
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

Background: Blood disorders like sickle cell disease and malaria affect many people around the world.

Locations

1 United States site

Age

18 to 70 Years

LEARN MORE
Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels

Background: Sickle cell disease can often be treated with blood stem cell transplants.

Locations

1 United States site

Age

4 to 80 Years

Phase

Phase 1/Phase 2

LEARN MORE
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)

The purpose of this study is to determine if a search strategy of searching for an HLA-matched unrelated donor for allogeneic transplantation if possible then an alternative donor if an HLA-matched unrelated donor is not available versus proceeding directly to an alternative donor transplant will result in better survival for allogeneic transplant recipients within 2 years after study enrollment.

Locations

49 United States sites

Phase

N/A

LEARN MORE
Best Noninvasive Predictor of Renal Function in Assessing Adult Sickle Nephropathy

Background: Sickle cell disease is a common inherited blood disorder.

Locations

1 United States site

Age

18 to 99 Years

Genotypes

Hb SS

LEARN MORE